EA202091395A1 - DERIVATIVES OF 1,3,4,5-TETRAHYDRO-2H-PYRIDO [4,3-b] INDOL FOR TREATMENT, RELIEF OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES SUCH AS ALZHEIMER'S DISEASE - Google Patents

DERIVATIVES OF 1,3,4,5-TETRAHYDRO-2H-PYRIDO [4,3-b] INDOL FOR TREATMENT, RELIEF OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES SUCH AS ALZHEIMER'S DISEASE

Info

Publication number
EA202091395A1
EA202091395A1 EA202091395A EA202091395A EA202091395A1 EA 202091395 A1 EA202091395 A1 EA 202091395A1 EA 202091395 A EA202091395 A EA 202091395A EA 202091395 A EA202091395 A EA 202091395A EA 202091395 A1 EA202091395 A1 EA 202091395A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alzheimer
disease
pyrido
indol
tetrahydro
Prior art date
Application number
EA202091395A
Other languages
Russian (ru)
Inventor
Сринивасачари Нампалли
Эмануэле Габелльери
Жером МОЛЕТТ
Original Assignee
Ас Иммьюн Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ас Иммьюн Са filed Critical Ас Иммьюн Са
Priority claimed from PCT/EP2019/050180 external-priority patent/WO2019134978A1/en
Publication of EA202091395A1 publication Critical patent/EA202091395A1/en

Links

Abstract

Настоящее изобретение относится к новым соединениям, которые можно применять для лечения, облегчения или профилактики группы расстройств и аномалий, связанных с агрегатами тау-белка (связанного с тубулином), включая, но не ограничиваясь этим, нейрофибриллярные клубки (NFT), например болезнь Альцгеймера (AD).The present invention relates to novel compounds that can be used to treat, alleviate or prevent a group of disorders and abnormalities associated with aggregates of tau protein (associated with tubulin), including, but not limited to, neurofibrillary tangles (NFT), such as Alzheimer's disease ( AD).

EA202091395A 2018-06-04 2019-01-04 DERIVATIVES OF 1,3,4,5-TETRAHYDRO-2H-PYRIDO [4,3-b] INDOL FOR TREATMENT, RELIEF OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES SUCH AS ALZHEIMER'S DISEASE EA202091395A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18175852 2018-06-04
PCT/EP2019/050180 WO2019134978A1 (en) 2018-01-05 2019-01-04 1, 3, 4, 5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer's disease

Publications (1)

Publication Number Publication Date
EA202091395A1 true EA202091395A1 (en) 2020-10-01

Family

ID=62530124

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091395A EA202091395A1 (en) 2018-06-04 2019-01-04 DERIVATIVES OF 1,3,4,5-TETRAHYDRO-2H-PYRIDO [4,3-b] INDOL FOR TREATMENT, RELIEF OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES SUCH AS ALZHEIMER'S DISEASE

Country Status (3)

Country Link
AR (1) AR117560A1 (en)
EA (1) EA202091395A1 (en)
TW (1) TWI812677B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036021A1 (en) * 2006-09-20 2008-03-27 Astrazeneca Ab Tetrahydro-lh-pyrido [3,4 -b] indole derivatives as cbl receptor ligands
TWI498328B (en) * 2008-01-25 2015-09-01 Medivation Technologies Inc New 2,3,4,5-tetrahydro-1h-pyrido(4,3-b)indole compounds and methods of use thereof
CA2745085C (en) * 2008-12-18 2018-03-06 Merck Patent Gmbh Tricyclic azaindoles
DK2558446T5 (en) * 2010-04-16 2019-12-09 Ac Immune Sa New compounds for the treatment of diseases associated with amyloid or amyloid-like proteins

Also Published As

Publication number Publication date
TW202017923A (en) 2020-05-16
TWI812677B (en) 2023-08-21
AR117560A1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
PH12020500573A1 (en) 1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer`s disease
WO2020176597A9 (en) N-substituted indoles and other heterocycles for treating brain disorders
EA202092557A1 (en) TETRAHYDROBENZOFURO [2,3-c] PYRIDINE AND BETA-CARBOLINE COMPOUNDS FOR TREATMENT, RELIEF OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU-PROTEIN UNITS
MX2021010193A (en) Azepino-indoles and other heterocycles for treating brain disorders.
MA42560A (en) COMPOSITIONS INCLUDING BACTERIAL STRAINS OF BLAUTIA FOR THE TREATMENT OF VISCERAL HYPERSENSITIVITY
EA201991375A1 (en) BICYCLO [1.1.1] PENTANE KINASE INHIBITORS CONTAINING A DOMAIN WITH TWO LEUCINE "Zipper" (DLK) FOR THE TREATMENT OF THE DISEASE
EA201691447A1 (en) 2-AMINO-3,5,5-TRIFTOR-3,4,5,6-TETRAGIDROPYRIDINES AS BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EA201990450A1 (en) KINASE INHIBITORS CONTAINING A DOMAIN WITH TWO LEUCINE "Zipper" (DLK) FOR THE TREATMENT OF A DISEASE
MX2021013422A (en) Kcnt1 inhibitors and methods of use.
MX2021013421A (en) Kcnt1 inhibitors and methods of use.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2017011598A (en) Methods for treating proteinopathies.
MX2019014300A (en) Agent for preventing or treating tauopathy.
CO2019014090A2 (en) Agents, uses and methods for treatment
WO2019075456A3 (en) Methods and substances for prevention and treatment of neurodegenerative diseases
MX2022011518A (en) Methods of treating proteinopathy- associated wandering.
EA202190576A1 (en) POLYMORPHIC COMPOUNDS AND THEIR APPLICATION
MX2019014306A (en) Amyloid-î² protein level decreasing agent.
MA38369A1 (en) Peptides and compositions for the treatment of a lesion of the joint
MX2021002652A (en) Use of casein kinase 1 inhibitors for treating vascular diseases.
WO2019165158A8 (en) Il-6 inhibitors and methods of treatment
EA202090555A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING BETA AMYLOID ANTIBODIES
EA202091395A1 (en) DERIVATIVES OF 1,3,4,5-TETRAHYDRO-2H-PYRIDO [4,3-b] INDOL FOR TREATMENT, RELIEF OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES SUCH AS ALZHEIMER'S DISEASE
MA55351A (en) NOVEL COMPOUNDS FOR THE TREATMENT, RELIEF OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU PROTEIN AGGREGATES
MX2021007460A (en) Peptides for treatment and prevention of diabetes and associated disorders.